Illumina (NASDAQ:ILMN) Given New $90.00 Price Target at Robert W. Baird

Illumina (NASDAQ:ILMN) had its price target lowered by analysts at Robert W. Baird from $127.00 to $90.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “neutral” rating on the life sciences company’s stock. Robert W. Baird’s target price would indicate a potential upside of 6.32% from the stock’s current price.

Several other equities analysts also recently weighed in on the company. Canaccord Genuity Group dropped their price target on Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a research report on Friday, February 7th. HSBC downgraded Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target for the company. in a research report on Friday, February 28th. Morgan Stanley dropped their price target on Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 11th. Guggenheim dropped their price target on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Finally, UBS Group raised their price target on Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $149.25.

Illumina Stock Performance

NASDAQ ILMN opened at $84.65 on Wednesday. Illumina has a 1-year low of $80.18 and a 1-year high of $156.66. The company has a market capitalization of $13.41 billion, a P/E ratio of -11.02, a PEG ratio of 1.60 and a beta of 1.17. The business has a 50 day moving average price of $119.36 and a 200 day moving average price of $131.84. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Sell-side analysts expect that Illumina will post 4.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ILMN. Versant Capital Management Inc boosted its holdings in Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 146 shares during the last quarter. Golden State Wealth Management LLC acquired a new position in Illumina in the fourth quarter valued at $32,000. Fourth Dimension Wealth LLC acquired a new position in Illumina in the fourth quarter valued at $40,000. Assetmark Inc. boosted its holdings in Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after acquiring an additional 296 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Illumina during the fourth quarter worth about $45,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.